Compound Identity
CJC-1295 at a Glance
CJC-1295 is a synthetic 30-amino-acid tetrasubstituted analog of growth hormone releasing hormone (GHRH). Four amino acid substitutions confer resistance to enzymatic degradation. Available in two forms — with DAC (Drug Affinity Complex) for extended half-life, or without DAC (identical to Mod GRF 1-29).
Compound Class
Growth hormone releasing hormone (GHRH) analog
Molecular Formula (no DAC)
C₁₅₂H₂₄₉N₄₄O₄₂
Molecular Weight (no DAC)
3,367.9 Da
Molecular Weight (with DAC)
~3,647 Da (includes MPA linker)
Amino Acid Length
30 residues (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys)
Receptor Target
Growth hormone releasing hormone receptor (GHRHR) — pituitary somatotroph
Key Modifications
D-Ala-2, Gln-8, Ala-15, Leu-27 substitutions prevent DPP-IV and endopeptidase cleavage
Research Background
Published Literature
Peer-reviewed research characterizes CJC-1295's receptor pharmacology, biochemistry, and biological activity across multiple domains. Sequence Labs supplies research-grade material; all product use is subject to laboratory research protocols and applicable regulations.
GHRHR Activation
CJC-1295 binds pituitary GHRHR with affinity comparable to native GHRH, activating Gs-coupled cAMP signaling and driving GH release from somatotroph cells.
DAC Extension
The DAC (Drug Affinity Complex) form contains an N-terminal maleimidopropionic acid (MPA) group that covalently binds serum albumin lysine residues, extending circulating half-life from ~7 minutes (native GHRH) to approximately 8 days.
Pulsatile vs Sustained
Non-DAC CJC-1295 (Mod GRF 1-29) preserves the pulsatile GH release pattern. DAC CJC-1295 produces sustained GHRH receptor stimulation — a distinct pharmacological profile used in research.
IGF-1 Elevation
Published research documents sustained IGF-1 elevation for approximately 6 days following a single DAC dose, reflecting persistent GH pulse activity.
Independent research publications on CJC-1295 are indexed in the NIH PubMed database. Consult primary literature for detailed methodology, dosing, and outcomes across research contexts.
Search PubMedSequence Labs Supply
Available Vial Sizes
All vials lyophilized under nitrogen with silver aluminum crimp cap and ivory-label spec. Manufacture and expiration dates printed. Batch-specific COA published in the COA library.
CJC-1295 (no DAC)
5 mg
$45 / vial
Also known as Mod GRF 1-29. Standard research vial.
CJC-1295 (no DAC)
10 mg
$75 / vial
Bulk research vial. Same 4-substitution sequence.
CJC-1295 (with DAC)
5 mg
$85 / vial
Extended half-life DAC form. ~8 day sustained receptor stimulation.
CJC-1295 (with DAC)
10 mg
$145 / vial
Bulk DAC vial. Research-institution volume.
Quality Standards
HPLC + Mass Spec
Every batch, reverse-phase HPLC purity confirmation plus MS molecular weight identity. Chromatograms published.
ISO 17025 Lab
Analytical testing performed by ISO 17025 accredited independent laboratory. Full documentation.
Cold-Chain Shipped
Insulated packaging with -20°C gel packs. 3-day standard, overnight available.
Silver Crimp Caps
Tamper-evident silver aluminum crimp caps. Lyophilized under nitrogen. Ivory-label spec.
Reconstitution Reference
Standard Procedure
Reconstitution protocol for research-grade lyophilized CJC-1295. Adjust diluent volume to reach the working concentration required by the research protocol.
Prepare Materials
Remove vial from cold storage. Allow to reach room temperature (~15-20 min). Sterile syringe ready.
Sterilize
Swab rubber stopper of both peptide vial and bacteriostatic water vial with 70% isopropyl alcohol.
Draw Diluent
For a 5 mg vial with 2 mL diluent: working concentration is 2,500 mcg/mL (2.5 mg/mL). Adjust diluent volume to preferred concentration for the research protocol.
Add Diluent Slowly
Inject the diluent down the inner vial wall. Never spray directly onto the lyophilized cake. Do not shake.
Gentle Dissolution
Swirl gently for 30-60 seconds until fully clear. CJC-1295 dissolves readily in bacteriostatic water.
Label + Store
Label vial with reconstitution date and concentration. Refrigerate 2-8°C. Reconstituted stability: ~4 weeks refrigerated for non-DAC; ~3 weeks for DAC form.
Frequently Asked Questions
CJC-1295 FAQ
What is the difference between CJC-1295 with DAC and without DAC?
Without DAC, CJC-1295 is chemically identical to Mod GRF 1-29 (the 29-30 amino acid modified GHRH sequence) with a half-life of approximately 30 minutes. With DAC (Drug Affinity Complex), an N-terminal MPA linker covalently binds circulating albumin, extending half-life to approximately 8 days.
Why the four amino acid substitutions?
Native GHRH is degraded within minutes by DPP-IV (cleaves after position 2) and endopeptidases. D-Ala-2 blocks DPP-IV cleavage. Gln-8, Ala-15, and Leu-27 stabilize against endopeptidase attack. Together they extend the base peptide half-life ~5-6 fold before DAC.
Is CJC-1295 the same as Sermorelin?
No. Sermorelin is GHRH(1-29) — the native sequence, unmodified. CJC-1295 is a tetrasubstituted GHRH(1-29) analog. Sermorelin has a much shorter half-life (~10-15 minutes) than either form of CJC-1295.
How does CJC-1295 differ from Ipamorelin?
Different mechanism. CJC-1295 is a GHRH analog binding the GHRHR receptor. Ipamorelin is a growth hormone secretagogue receptor (GHSR / ghrelin receptor) agonist. They act at different receptors and are often studied together to compare pathways.
What testing is done on each CJC-1295 batch?
HPLC purity (typical >98%), mass spectrometry (target 3,367.9 Da for no-DAC, ~3,647 Da for DAC), endotoxin (LAL), water content by Karl Fischer, residual TFA, appearance. Full COA published.
Order CJC-1295 Research Material
Batch-tested lyophilized vials with published COA. Standard 3-day cold-chain shipping $15. Overnight $30. Same-day dispatch on orders before 2pm ET.